17,32 $
3,22 % vorgestern
NYSE, 24. Oktober, 22:00 Uhr
ISIN
US03969F1093
Symbol
RCUS
Berichte

Arcus Biosciences Aktie News

Neutral
Business Wire
7 Tage alt
TOKYO & HAYWARD, Calif.--(BUSINESS WIRE)--Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Arcus Biosciences, Inc. (NYSE:RCUS, “Arcus”) announced that Taiho exercised its option to develop and, if approved, commercialize casdatifan (International Nonproprietary Name; development code: AB521), an investigational small molecule HIF (Hypoxia Inducible Factor)-2α inhibitor, in Japan and certain other t...
Positiv
Seeking Alpha
10 Tage alt
Arcus Biosciences (RCUS) boasts a diverse, promising pipeline with key candidates like domvanalimab, casdatifan, and quemliclustat advancing in pivotal trials. Recent data from RCUS's EDGE-Gastric trial show strong survival benefits, with major readouts from large phase 3 studies expected in 2026. RCUS is well-capitalized with nearly $1 billion in liquid assets, but its high cash burn suggests ...
Neutral
Business Wire
14 Tage alt
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced the first OS results from Arm A1 of the Phase 2 EDGE-Gastric study in patients with locally advanced unresectable or metastatic gastric, gastroesophageal junct...
Neutral
Business Wire
17 Tage alt
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 60,300 shares of the Company's common...
Positiv
Investors Business Daily
19 Tage alt
Arcus Biosciences shares climbed Tuesday as enthusiasm grows for the biotech company's experimental cancer drug, a rival to Merck.
Neutral
Seeking Alpha
20 Tage alt
Arcus Biosciences, Inc. (NYSE:RCUS ) Shareholder/Analyst Call October 6, 2025 10:00 AM EDT Company Participants Pia Eaves - Vice President of Investor Relations & Strategy Terry Rosen - Co-Founder, Chairman & CEO Richard Markus - Chief Medical Officer Jennifer Jarrett - Chief Operating Officer Juan Jaen - Co- Founder & President Conference Call Participants Rana McKay Yigal Nochomovitz - Citigr...
Neutral
Business Wire
20 Tage alt
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced new monotherapy data for casdatifan, a HIF-2a inhibitor with best-in-class potential, in late-line metastatic clear cell renal cell carcinoma (ccRCC). At an inves...
Neutral
Business Wire
etwa ein Monat alt
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted two new employees options to purchase a total of 9,750 shares of the Company's common ...

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen